Transforming medicine and changing lives


June 3, 2022

AskBio CEO and Co-Founder Sheila Mikhail receives 2022 Entrepreneurial Award  from University of Chicago Booth School of Business

Prestigious recognition for outstanding professional achievement in the formation of a successful enterprise awarded to Booth School of Business Alumni Research Triangle Park, N.C. – June 2, 2022 – Asklepios BioPharmaceutical, Inc. (AskBio), an independently operated subsidiary of Bayer AG, today announced that CEO and Co-Founder Sheila Mikhail was recognized by the University of Chicago Booth School of Business for outstanding professional achievement among its alumni. As a 1993 finance MBA graduate with honors, Ms. Mikhail has been recognized with the 2022 Entrepreneurial Award.  “This award is tremendously meaningful as the Booth School of Business is one of the nation’s top ranked business schools,” said AskBio Co-Founder and CEO Sheila Mikhail. “The award is a reflection of the accomplishments that could not be possible without the support of a world-class team at AskBio as we continue to advance our research, clinical candidates and manufacturing capabilities.” Ms. Mikhail earned a JD with honors from Northwestern University, a finance MBA with honors from the University of Chicago, and a BS with highest honors from the University of Illinois at Urbana-Champaign. She co-founded AskBio in 2001 with Dr. R. Jude Samulski, who is considered one of the leading pioneers for AAV gene therapy technology.  Since co-founding AskBio, and under the leadership of Ms. Mikhail, the company, including its manufacturing facilities, has grown to employ over 700 biotech professionals operating in five countries. Eighteen months after closing a series A funding round of $235 million in April 2019, Ms. Mikhail orchestrated a $4 billion acquisition by Bayer AG in October 2020.  Under Ms. Mikhail’s leadership, AskBio is flourishing with an expansive gene therapy technology toolbox, three state-of-the-art manufacturing facilities in San Sebastian Spain and a robust therapeutic pipeline, all at various clinical stages, to treat Pompe Disease, Limbe Girdle Muscular Dystrophy, Multiple System Atrophy, Congestive Heart Failure, Huntington’s Disease, and Parkinson’s Disease. “In my view, Sheila is one of the most accomplished Biotech executives in the industry,” commented Dr. Samulski, AskBio’s Co-Founder and Chief Scientific Officer. “The recognition by University of Chicago Booth School of Business is a testament of her unparalleled business acumen combined with her significant command of genetic science” The Distinguished Alumni awards are only available to graduates of Chicago Booth. The Entrepreneurial Award is given to a person who has demonstrated professional achievement of the highest caliber in the management and formation of a successful enterprise and is recognition by colleagues and peers for outstanding leadership and administrative abilities.  About AskBio  Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG acquired in 2020, is a fully integrated gene therapy company dedicated to developing life-saving medicines that cure genetic diseases. The company maintains a portfolio of clinical programs across a range of neuromuscular, central nervous system, cardiovascular and metabolic disease indications with a clinical-stage pipeline that includes therapeutics for Pompe disease, Parkinson’s disease, and congestive heart failure. AskBio’s gene therapy platform includes Pro10™, an industry-leading proprietary cell line manufacturing process, and an extensive capsid and promoter library. With global headquarters in Research the news

We are on a never-ending quest to advance genetic technology

and life-saving AAV gene therapy

In 1984, Dr. Jude Samulski, one of AskBio’s visionary founders, asked if a virus could be used to erase genetic disease. Discovering the answer cleared the path for historic advances in genetic medicine, and AskBio is leading the way.

Learn about AskBio »

gene therapy

Revolutionizing gene therapy

Cures for life-altering diseases depend on new technology to lower the cost of treatment and increase supply for every patient who needs it.

Explore our technology »

Clinical Pipeline

Changing lives

Our clinical pipeline is the direct result of listening to patients, their families, their care teams and disease-advocacy organizations.

Discover our pipeline »

Putting patient care first

The voices of patients drive everything we do. They propel our research and the urgent need to find cures.

For Patients »

Work with us

Advancing research

Today’s genetic discoveries are some of the most awe-inspiring advances in medical history. We welcome collaboration with innovative minds in genetic R&D.

Building careers

Help transform the face of healthcare with life-changing gene therapy. Every life enriched by our scientific advancements is a result of someone like you.


There are no upcoming events.